U.S. Markets close in 2 hrs 36 mins

Ironwood Pharmaceuticals, Inc. (IRWD)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.46-0.39 (-2.46%)
As of 1:23PM EDT. Market open.
People also watch
INFIEPZMAEGRMNTASGYP
Full screen
Previous Close16.24
Open15.91
Bid15.49 x 200
Ask15.51 x 100
Day's Range15.39 - 15.91
52 Week Range12.48 - 19.94
Volume567,374
Avg. Volume1,207,551
Market Cap2.31B
Beta1.47
PE Ratio (TTM)-15.84
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube6 days ago

    ETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ironwood Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IRWD-US. Comparing the performance and risk of Ironwood Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
    Capital Cube8 days ago

    Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017

    Categories: Yahoo FinanceGet free summary analysis Ironwood Pharmaceuticals, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Ironwood Pharmaceuticals, Inc. – Progenics Pharmaceuticals, Inc., Synergy Pharmaceuticals, Inc., Nektar Therapeutics, Astrazeneca PLC Sponsored ADR, Sucampo Pharmaceuticals, Inc. Class A, Cumberland Pharmaceuticals Inc. and Synthetic Biologics, Inc. ... Read more (Read more...)

  • Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?
    Zacks15 days ago

    Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?

    Ironwood (IRWD) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.